KRAS Mutations, Potential Biomarkers for the Identification of Non-small-Cell Lung Cancer Patients That May Benefit From Immunotherapy-Based Treatments

KRAS Mutations, Potential Biomarkers for the Identification of Non-small-Cell Lung Cancer Patients That May Benefit From Immunotherapy-Based Treatments

Saved in:

Bibliographic Details
Main Authors:	L. Robado De Lope, R. Serna-Blasco, P. Mediavilla, V. Calvo, A. Collazo-Lorduy, S. Peña Cabia, P. Diz Tain, V. González-Rumayor, A. Romero, M. Provencio
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	The Journal of Liquid Biopsy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195423000516
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Liquid Biopsy Analysis Shows MAGI2 Gene as Potential Negative Prognosis Biomarker in NSCLC Patients
by: P. Mediavilla, et al.
Published: (2023-11-01)

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01)

Role of silent mutations in KRAS-mutant tumors
by: Jun Lu, et al.
Published: (2025-02-01)

Wireless May Benefit Blockchain
by: Seungmo Kim, et al.
Published: (2024-12-01)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
by: Kohei Maruyama, et al.
Published: (2025-01-01)

The opposite association of HRAS and KRAS mutations with clinical variables of bladder cancer
by: M. P. Smal, et al.
Published: (2015-12-01)

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01)

A short history of »Kras«
by: Andrej Kranjc
Published: (2018-12-01)

To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic
by: Mariano Provencio, et al.
Published: (2021-02-01)

KRAS mutations in patients with AML: clinical characteristics and not reported mutations using NGS
by: Salma Said Ibrahim Elsayed, et al.
Published: (2024-12-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

Viral mimicry evasion: a new role for oncogenic KRAS mutations
by: Raymond Chen, et al.
Published: (2025-02-01)

Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
by: Han Koo, et al.
Published: (2025-01-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
by: Shangshang Ma, et al.
Published: (2024-12-01)

p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
by: Özgün Le Roux, et al.
Published: (2024-01-01)

KRAS Transitions and Villous Growth in Colorectal Adenomas
by: Mauro Risio, et al.
Published: (2005-01-01)

Identification of cave pollution in the Kras Plateau, Slovenia
by: Jure Tičar, et al.
Published: (2018-12-01)

Motif-guided identification of KRAS-interacting proteins
by: Sanan Wu, et al.
Published: (2024-11-01)

Mutasi gen KRAS pada kanker kolorektal
by: Ni Nyoman Ayu Dewi, et al.
Published: (2021-07-01)

Effect of KRAS mutation status on clinicopathological characteristics and overall survival in patients with rectal cancer
by: Shengbin Zheng, et al.
Published: (2025-01-01)

KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
by: Sarah Bouri, et al.
Published: (2020-01-01)

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
by: Daniele Calistri, et al.
Published: (2006-01-01)

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report
by: Andrea De Giglio, et al.
Published: (2024-12-01)

Benefit of immunotherapy for advanced melanoma in two patients with xeroderma pigmentosum
by: A.C. Rivas Segovia, et al.
Published: (2024-01-01)

Association of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues
by: Vahideh Hamidi Sofiani, et al.
Published: (2024-12-01)

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
by: Nicolas Piton, et al.
Published: (2015-01-01)

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer
by: Guomin Gu, et al.
Published: (2024-12-01)

Probable autoimmune lymphoproliferative syndrome with monogenic lupus due to KRAS mutation - A rare encounter
by: Amiya Nayak, et al.
Published: (2024-02-01)

Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01)

Intratumor heterogeneity in KRAS signaling shapes treatment resistance
by: Oleksi Petrenko, et al.
Published: (2025-02-01)

Degree of technological implementation in intravenous chemotherapy management in hospitals of the Autonomous Community of Madrid
by: Silvia Peña-Cabia, et al.
Published: (2017-07-01)

Emerging Mechanisms of Physical Exercise Benefits in Adjuvant and Neoadjuvant Cancer Immunotherapy
by: Fabio Casciano, et al.
Published: (2024-11-01)

The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report
by: Ahmed N. Alkhasawneh, et al.
Published: (2012-01-01)

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
by: Linyan Tian, et al.
Published: (2025-01-01)

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells
by: Dominic Leiser, et al.
Published: (2015-08-01)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
by: Ullas Batra, et al.
Published: (2023-02-01)

Cell-Free (cfDNA) Based Evaluation of KRAS Mutation Profile in Solid Tumors With Focus on G12C Variant
by: S. Limaye, et al.
Published: (2023-11-01)

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
by: Qinglong Ma, et al.
Published: (2025-01-01)

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
by: Maximilian Kramer‐Drauberg, et al.
Published: (2025-02-01)